Opinion|Videos|January 18, 2024

Updates on Combination Treatment Approaches with BTKi + Venetoclax

Author(s)Sameer A. Parikh, MD, Sikander Ailawadhi, MD, Mazie Tsang, MD, MAS, MS

Expert faculty highlight key updates from trials evaluating combination therapy approaches using venetoclax plus a BTKi in the frontline setting.

Episodes in this series

EP. 1 Evolving Front-line Treatment Options for CLL

EP. 1 Evolving Front-line Treatment Options for CLL

EP. 2 Navigating 1L Treatment Selection with BTKis in CLL

EP. 2 Navigating 1L Treatment Selection with BTKis in CLL

EP. 3 Updates on BTKi Monotherapy for CLL in the Frontline Setting

EP. 3 Updates on BTKi Monotherapy for CLL in the Frontline Setting

EP. 4 The Role of BTKi + Obinutuzumab for 1L Treatment of CLL

EP. 4 The Role of BTKi + Obinutuzumab for 1L Treatment of CLL

EP. 5 Expert Perspectives on Fixed Duration Therapy with Venetoclax + Obinutuzumab

EP. 5 Expert Perspectives on Fixed Duration Therapy with Venetoclax + Obinutuzumab

EP. 6 Updates on Combination Treatment Approaches with BTKi + Venetoclax

EP. 6 Updates on Combination Treatment Approaches with BTKi + Venetoclax

$EP. 7 Navigating Treatment Selection for CLL in the Relapsed/Refractory Setting$

EP. 7 Navigating Treatment Selection for CLL in the Relapsed/Refractory Setting

EP. 8 Expert Insights on Extended Follow-Up Data from ALPINE and ELEVATE-RR

EP. 8 Expert Insights on Extended Follow-Up Data from ALPINE and ELEVATE-RR

EP. 9 Consideration Factors in Treatment Selection for BTKi Therapy in R/R CLL

EP. 9 Consideration Factors in Treatment Selection for BTKi Therapy in R/R CLL

EP. 10 Key Considerations in Managing Hypertension Risk with BTKis in CLL

EP. 10 Key Considerations in Managing Hypertension Risk with BTKis in CLL

EP. 11 Expert Perspectives on Managing Risk of Atrial Fibrillation with BTKis in CLL

EP. 11 Expert Perspectives on Managing Risk of Atrial Fibrillation with BTKis in CLL

EP. 12 Managing Bleeding Risk in Patients with CLL on BTKi Therapy

EP. 12 Managing Bleeding Risk in Patients with CLL on BTKi Therapy

EP. 13 Utilizing Real-World Data for Informed Decision-Making in CLL

EP. 13 Utilizing Real-World Data for Informed Decision-Making in CLL

EP. 14 Navigating Treatment Resistance and Sequencing in CLL

EP. 14 Navigating Treatment Resistance and Sequencing in CLL

EP. 15 Advancements with Novel Treatment Approaches in CLL

EP. 15 Advancements with Novel Treatment Approaches in CLL

EP. 16 Future Perspectives and Unmet Needs in CLL

EP. 16 Future Perspectives and Unmet Needs in CLL

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Related to this article

Acute Myeloid Leukemia | Image Credit: © LASZLO - stock.adobe.com.

November 6th, 2026

Tambiciclib Combo Shows Activity in Relapsed/Refractory Post-Venetoclax AML

Investigators will present detailed findings from a phase 2 study assessing a tambiciclib-based regimen in patients with relapsed/refractory AML at ASH 2026.

Trending on CancerNetwork

FDA Approves OncoMate MSI Dx as Pembrolizumab Companion Diagnostic in MSI-H Solid Tumors

FDA Approves Pimicotinib for Tenosynovial Giant Cell Tumors

Hyperthermic Mitomycin C Yields 68% 1-Year HG-RFS in BCG-Unresponsive NMIBC

Acylfulvene Prodrug LP-184 Shows Tolerability in Recurrent Glioblastoma

European Commission Expands Melflufen Label to Third-Line Multiple Myeloma